Boral Anthony L. 4
4 · Blueprint Medicines Corp · Filed Sep 24, 2020
Insider Transaction Report
Form 4
Boral Anthony L.
Sr. VP, Clinical Development
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-09-22−6,864→ 17,483 totalExercise: $15.01Exp: 2026-02-03→ Common Stock (6,864 underlying) - Exercise/Conversion
Common Stock
2020-09-22$15.01/sh+6,864$103,029→ 25,828 total - Sale
Common Stock
2020-09-22$82.33/sh−6,864$565,113→ 18,964 total
Footnotes (2)
- [F1]Effected pursuant to a trading plan adopted on March 17, 2020 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]This option was granted on February 3, 2016. This option is fully vested as of the date hereof.